Latest news with #patents
Arab News
3 days ago
- Business
- Arab News
Saudi efforts to boost innovation pay off
RIYADH: Support provided by Saudi authorities for scientific research, innovation and university teaching have been credited for recent achievements by innovators in the Kingdom. Official figures show that 8,029 patent applications were submitted in the country in 2024, an increase of 13.3 percent on the previous year. In addition, 31,834 trademarks and 1,578 industrial designs were registered, and 4,355 patents were published. Investment in research and development in Saudi Arabia increased to SR22.6 billion ($6 billion) in 2023, a 17.4 percent increase compared with 2022. Recent examples of Saudi innovators honored with awards for research and innovation at international events included ophthalmologist Dr. Saad Al-Anzi, who won the grand prize at the Geneva International Exhibition in April this year for inventing a cost-effective surgical tool for cataract operations, while six other Saudi innovators received global awards at the event and 134 received global medals. And 39 students from King Abdulaziz University received a global award at the IENA Expo for ideas, inventions and new products in Germany last October.
Yahoo
4 days ago
- Business
- Yahoo
Mass Megawatts Announces Three Patent Pending Innovations Toward Reducing Solar Desalination Cost to Be the Same as Tap Water in the $26 Billion Desalination Market
Worcester, Massachusetts--(Newsfile Corp. - June 25, 2025) - Mass Megawatts (OTC Pink: MMMW) announces three new patent pending innovations with the goal toward reducing the cost of the Solar Desalination to the same cost as tap water. Two of the new innovations are related to wind energy and aerodynamic principles. The third innovation is related to solar technology and solar albedo effect analysis. The global Desalination market, currently valued at $26 billion a year, is expected to grow to more than $40 billion before 2033. Several devices have been introduced to efficiently desalinate salt water and attempt to eliminate the clogging of the desalination process with the accumulation of salt on parts of the system during the process using a substantial amount of electricity and expensive materials. Recent advances avoiding the cost of electricity and expensive material hold significant promise for low-cost seawater desalination. However, salt accumulation is a key obstacle for reliable adoption. Our new technology demonstrates a more efficient method of salt transport enabled with localized solar concentration and salt rejection. It also offers a strategy for high performance solar evaporation. The primary goal is removing the "salt foul" caused by the salt accumulation which is largely caused by slow moving water with an increasing salt density due to the ongoing evaporation in the solar desalination process. At the same time, the new technology uses low-cost materials to reduce the capital cost of the solar desalination units. With the objective of reducing each square meter of the solar desalination unit to a cost of less than four dollars, desalinated water can be delivered at a cost less than tap water. In three specific areas, the new technologies are a serious improvement of the most advanced recent research in solar desalination technologies of passive salt rejection techniques. One innovation uses wind energy related aerodynamic principles for creating an optimal shape for the microchannel diffusers toward enhancing aquadynamic (water related aerodynamic behavior). The new technology reduces turbulence for more salt efficient salt rejection. It is an important step toward avoiding salt accumulation on the solar desalination process. Specifically, using an aerodynamically optimal shaped microchannels, the salt can be pulled rather than pushed through the microchannels like a wind diffuser pulling air through a small tunnel area since the pressure is lower with less salt particles on the cold side of the barrier with microchannels. The aerodynamic enhancing shape of both the input area (upper hot area) and the diffuser (lower cold bulk water area) allows a swift and steady salt rejection without the turbulence of previous methods that would slow down the salt rejection process and cause salt accumulation. The second innovation related to wind power is the understanding of the power cubed formula and its strong impact in the development of a redundancy reinforcement to prevent salt accumulation facilitated by the swift underwater movement of the platforms of microchannel diffusers twice a day during a cleaning process near the time of low tide. Using independent floats for the solar heating platform and the microchannel diffuser platforms, the twice a day cleaning process can be performed. The third innovation is related to solar energy. The new solar desalination system uses a low cost and optimally shaped stationary solar reflectors in conjunction to an optimally shaped heated surface area of the solar desalination process for turbocharging the salt rejection process. Using the Mass Megawatts solar tracker shown on our company's web site there can be further improvement of the solar desalination performance for a small additional cost. The company's Solar Tracking System (STS) is a new patent pending product that significantly reduces the payback period for solar power investments. It is designed to automatically adjust the position of solar panels to directly face the sun as it travels from East to West throughout the day. Unlike other solar tracking technologies, the Mass Megawatts Solar Tracker utilizes a low-cost framework that adds stability to the overall system, while improving energy production levels. This press release contains forward-looking statements that could be affected by risks and uncertainties. Among the factors that could cause actual events to differ materially from those indicated herein are: the failure of Mass Megawatts Wind Power (MMMW), also known as Mass Megawatts Windpower, to achieve or maintain necessary zoning approvals with respect to the location of its power developments; the ability to remain competitive; to finance the marketing and sales of its electricity; general economic conditions; and other risk factors detailed in periodic reports filed by Mass Megawatts Wind Power (MMMW). Contact: info@ To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
6 days ago
- Business
- Associated Press
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms, is pleased to announce that it has received 2 new international patents. This now brings Lexaria's total worldwide patent portfolio to 50. 'We are pleased to announce the addition of these patents as we continue to execute on our strategy to broaden Lexaria's patent portfolio. We believe that this not only increases our likelihood of entering into commercial deals within the pharmaceutical industry, but that it also serves as an important building block for establishing and protecting long-term value for our shareholders and all stakeholders,' said Rich Christopher, CEO of Lexaria. 'The achievement of 50 worldwide patents marks the accomplishment of a milestone that had been envisioned by the Company's management for over a decade.' Lexaria has been granted a new patent in Australia within its patent family #24, Compositions and Methods for Treating Epilepsy. This broadens Lexaria's intellectual property protection for the use of its DehydraTECH™ enhanced processing technology related to the treatment of epilepsy outside of the USA, where a strong patent portfolio of 6 existing patents has already been built. This new patent will expire in 2044. Lexaria has also been granted a new patent in Japan within its patent family #20, Compositions and Methods for Sublingual Delivery of Nicotine. This patent joins already-existing patents within the same family in both the USA and Canada. This new patent will expire in 2043. The epilepsy drug market was US$9.5 billion in 2023 and is expected to reach sales of over $15 billion by 2032. Approximately 50 million people in the US alone are affected by epilepsy. The global retail oral nicotine market was valued at US$5.5 billion in 2023 and is expected to grow at 26%/yr until at least 2030, with additional revenue generated within the medically-prescribed market. The nicotine pouch market alone - where DehydraTECH™ has demonstrated absorption benefits in earlier studies - is expected to reach US$25.4 billion in revenue by 2030. Altria Ventures Inc. the 16.67% shareholder of Lexaria Nicotine LLC, holds a non-exclusive license to the use of DehydraTECH with nicotine products. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients enter the bloodstream through oral delivery. Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic - Head of Investor Relations [email protected] Phone: 250-765-6424, ext 202 SOURCE: Lexaria Bioscience Corp. press release
Yahoo
19-06-2025
- Business
- Yahoo
Blue Biofuels Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent
PALM BEACH GARDENS, FL, June 18, 2025 (GLOBE NEWSWIRE) -- Blue Biofuels, Inc. (OTCQB: BIOF). Blue Biofuels is proud to announce the issuance of a new United States patent, further strengthening the company's expanding intellectual property portfolio. This latest patent brings the company's total number of granted patents to seven, with an additional 25 patent applications pending. Together, they form a robust IP foundation that underscores Blue Biofuels' commitment to safeguarding its pioneering biofuel technologies. The newly granted patent marks a significant milestone in the evolution of our proprietary process, which continues to advance in efficiency, scalability, and innovation. As our technology becomes increasingly sophisticated, the importance of securing comprehensive intellectual property protections grows, ensuring that our breakthroughs remain protected as we move toward commercial deployment. Building upon previously issued patents, this latest addition reinforces Blue Biofuels' leadership in the renewable energy sector and highlights our dedication to pushing the boundaries of sustainable fuel innovation. 'This new patent is a testament to the strength and originality of our CTS technology,' said Ben Slager, CEO of Blue Biofuels. 'Each step forward in building our intellectual property portfolio is a step toward securing our competitive advantage as we bring clean, cost-effective biofuels to market. Innovation and protection go hand-in-hand as we scale up.' As we continue to enhance and commercialize our technology, securing the intellectual assets that support our long-term growth and leadership remains a top priority. This new patent further positions Blue Biofuels at the forefront of the domestic clean energy transition. About Blue Biofuels, Inc. Blue Biofuels is based in Florida and has the goal to produce biofuels through its patented Cellulose-to-Sugar (CTS) technology and its licensed Vertimass technology as well as in VertiBlue Fuels, LLC, its 50:50 joint venture with Vertimass. CTS is a sustainable, and renewable green energy system with the potential to achieve a near-zero carbon footprint. The CTS process can convert cellulose from virtually any plant material – grasses, forestry products, and agricultural waste such as sugarcane bagasse and wheat straw — into sugars that are subsequently processed into biofuels, such as ethanol and, through the Vertimass Process, into sustainable aviation fuel. The CTS process is a patented and proprietary technology wholly owned by Blue Biofuels. Blue Biofuels' CTS technology represents significant progress in renewable energy, offering a sustainable solution that reduces reliance on food crops for ethanol production. By utilizing abundant and renewable biomass sources such as king grass, sugar cane bagasse, and corn stover, the company is positioned to contribute meaningfully to the global transition toward cleaner energy. This versatility allows the company to take advantage of feedstock variability in different locations around the US and the world. Special Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond the Company's control. The words 'believes', 'may', 'will', 'should', 'would', 'could', 'continue', 'seeks', 'anticipates', 'plans', 'expects', 'intends', 'estimates', or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved. Contact: Ben Slager, CEO and Chairman Ben@ Anthony Santelli, CFO Anthony@
Entrepreneur
18-06-2025
- Business
- Entrepreneur
How to Identify Patent-Worthy Innovations in Your Business
Here's how to know which innovations are truly worth protecting — before putting time and money into filings that may never pay off. Opinions expressed by Entrepreneur contributors are their own. Startups often rush to file patents while their product is still taking shape. The pressure can come from investor expectations or the instinct to claim a patent early. But I've seen too many founders spend $20,000 … $30,000 … protecting ideas that never reach the market. Being selective avoids that capital drain. A rushed filing may feel safe, but if product plans change or the market shifts, you've locked in a cost with little return. After 25+ years of helping startups protect what matters, I've developed a five-question filter to make smarter, more strategic patent decisions: Does it solve a technical problem with a technical solution? Will it still matter to the business in 2-20 years? Can it become foundational and reusable across products? Does it offer market differentiators over competitors? What are its chances of getting your application issued from the patent office? Here's how to think through these five questions. Related: The Basics of Protecting Your Intellectual Property, Explained 1. Is this innovation solving a technical problem with a technical solution? To ease pushback from the patent office, your invention should solve a technical problem with a technical solution. It must go beyond abstract ideas or human-centered processes to improve how a system, product or service functions. If it has advantages over known solutions, for example, efficient data processing, improved mechanical reliability or strengthening a component's structure, you're likely on solid ground. These differences affect how a product performs, not just what it does. In contrast, innovations focused on managing human activity, solving business problems or directing human effort are typically seen as business methods. The patent office applies a skeptical eye on these innovations such that a patent is unlikely. Take this case: Your delivery drone overheats on long routes. You redesign the motor housing to improve airflow and prevent failure. That's a concrete technical solution to a real technical problem and likely meets the first test for patent eligibility. Next, ask if it will still matter over time. 2. Will this innovation still matter to our Business in two to 20 years from now? Patents aren't overnight wins; most take two to three years — sometimes longer — to grant. By the time one is approved, will the idea still be relevant to your products and the industry? Many startups file early with a sense of urgency, but products evolve, markets shift, and priorities change. That innovative feature users love today may be irrelevant next year. That's why I always ask: Does this idea support your long-term business goals? Could it remain part of your core offering even if your roadmap changes? If the answer is yes, the idea is worth serious consideration. If not, you may be better off holding back your patent budget for the next big innovation. Related: 3.6 Million Patents Were Filed in 2023 Alone — This Is How the Most Successful Ones Got Approved 3. Could this innovation become foundational to be reused across multiple product lines? Some of the strongest patents I've seen aren't tied to a single product. They solve a technical problem that is foundational to the platform underlying entirely different product lines. Once issued, the patent strengthens the company's foundation. That's what I mean by "foundational." Maybe it starts in your core product but later shows up in a mobile app, internal dashboard or enterprise version. Same core capability reused again and again. If your team keeps finding new ways to build on it, it's likely worth protecting. A good example is Dyson's digital motor technology. It started in vacuum cleaners, then powered bladeless fans, hand dryers and hair tools. One patent family protected a core capability reused across distinct product lines, making it fundamental to the company's growth. If an innovation has that kind of scale, it's a strong patent candidate. Next, think about how it might give you leverage in the market. 4. Would this innovation give us leverage against competitors? One of the smartest things you can do as a startup founder is study your competitors' product strategy. What are they filing patents upon? What products are they prioritizing? And more importantly, what gaps are they missing? Filing into a soon-to-be-developed area can shift the power dynamic. You could secure a patent covering a capability they'll eventually need, and now you know the path they are pursuing. That opens the door to licensing discussions, cross-licensing deals or defensive leverage when the competition heats up. Because in competitive markets, patents aren't just legal protections. They're business tools. They create options for partnerships, revenue or pressure at the negotiating table. However, even the best-positioned idea can fail not because of merit but because of where it lands in the patent office for examination. Your odds drop sharply if your application is assigned to a technology area with a near-zero allowance rate. That's why this final question matters before you file. Related: 5 Ways to Improve Your Chances of Getting Patents 5. What are the odds of success for this idea at the patent office? Before you file, know how the idea is likely to perform at the patent office. That insight is now available long before a single claim is drafted. Modern predictor tools can now predict which USPTO art unit will handle your application with just a rough idea. These units vary widely in allowance rates, timelines and examiner behavior. Knowing where your application is likely to be assigned gives you a strategic edge. This becomes the final filter in identifying patent-worthy innovations. Prioritize ideas likely to land in favorable groups. Drop the ones facing rejection-heavy examiners and drawn-out prosecution. Predictor tools can help you refocus your claim direction in one that is likely to see more favorable consideration. No startup can afford to chase patents that burn time and budget. I strongly believe great ideas earn protection not just by being smart but by standing up to scrutiny from every angle. That's what true vetting looks like. Engineers weigh feasibility. Business teams assess strategic value. IP counsel analyzes legal strength. When all these perspectives align, strong patent decisions emerge. The five questions above are your shared framework. Answered across disciplines, they help surface innovations worth the time, cost and protection.
